Company makes spectroscopy acquisition

Renishaw's investment in D3 will comprise cash of GBP 1.85 million and instrumentation, with a combined value of approximately GBP 5 million over the next five years.

Renishaw has acquired a 75% interest in D3 Technologies, a company set up in collaboration with the University of Strathclyde and others to exploit certain patents related to Surface enhanced Raman spectroscopy (SERS) and to develop SERS for molecular diagnostics and trace detection.

Renishaw's investment in D3 will comprise cash of GBP 1.85 million and instrumentation, with a combined value of approximately GBP 5 million over the next five years.

Part of the investment has been used by D3 to purchase for GBP 850,000 the business and assets of the analytical business unit (ABU) operated by Mesophotonics, a spin-out company from the University of Southampton.

The ABU develops and manufactures substrates used in SERS applications.

Combining the SERS technology and biochemistry expertise of the University of Strathclyde with the Klarite substrate technology of Mesophotonics ABU offers a broad range of product opportunities to exploit in the growing healthcare diagnostics and forensic markets.

As a leading supplier of Raman instrumentation Renishaw has a vested interest in the furtherance of Raman spectroscopy and its applications into new and developing markets.

Renishaw's principal business is the design, manufacture and sale of advanced precision metrology and inspection equipment and analytical systems.

Over 90% of its sales are exported internationally through its world-wide network of subsidiaries and distributors.

Back to top